Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 12/20 | 0.43 |
| ▸ | SCD | O00767 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789762 | 0.83 | HRH3 (0.50) | DCTPP1SCD | |
| SCHEMBL1788622 | 0.80 | DGAT2 (0.42) | MAPK14TP53 | |
| SCHEMBL1789742 | 0.79 | HPGD (0.51) | MAPK14 | |
| SCHEMBL1792348 | 0.78 | CYP1A2 (0.51) | TP53 | |
| SCHEMBL1789862 | 0.78 | SMN1; SMN2 (0.50) | TP53 | |
| SCHEMBL1789972 | 0.78 | KMT2A (0.42) | MAPK14 | |
| SCHEMBL1790517 | 0.78 | LMNA (0.51) | MAPK14TP53 | |
| SCHEMBL1791796 | 0.77 | KMT2A (0.41) | MAPK14 | |
| SCHEMBL1789911 | 0.77 | TP53 (0.38) | MAPK14TP53 | |
| SCHEMBL1788446 | 0.76 | ACE2 (0.53) | MAPK14TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | DCTPP1 4868/4885SCD 3758/4885MAPK14 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.